用于帕金森病的神经移植
Neural transplantation for Parkinson's disease.
作者信息
Date I, Ohmoto T
机构信息
Department of Neurological Surgery, Okayama University Medical School, Japan.
出版信息
Cell Mol Neurobiol. 1999 Feb;19(1):67-78. doi: 10.1023/a:1006964507916.
Abstract
- Neural transplantation is one promising approach for the treatment of Parkinson's disease. Fetal substantia nigra cells are a good source of dopamine, but in order to avoid ethical and immunological problems, adrenal medullary chromaffin cells have been investigated as an alternative source. 2. Grafted adrenal medullary chromaffin cells can provide dopamine as well as several neurotrophic factors that affect dopaminergic neurons in the brain. 3. We review experimental studies for application of neural transplantation techniques in Parkinson's disease, including immunological studies, cryopreservation, microvasculature, donor tissue, and direct gene delivery studies performed in our laboratory. Our clinical experience and new approach involving a polymer-encapsulated cell grafting procedure are also described.
摘要
- 神经移植是治疗帕金森病的一种有前景的方法。胎儿黑质细胞是多巴胺的良好来源，但为了避免伦理和免疫问题，肾上腺髓质嗜铬细胞已被作为替代来源进行研究。2. 移植的肾上腺髓质嗜铬细胞可以提供多巴胺以及几种影响脑中多巴胺能神经元的神经营养因子。3. 我们回顾了神经移植技术在帕金森病中应用的实验研究，包括我们实验室进行的免疫学研究、冷冻保存、微血管系统、供体组织和直接基因递送研究。还描述了我们的临床经验以及涉及聚合物包裹细胞移植程序的新方法。
相似文献
1
Neural transplantation for Parkinson's disease.
Cell Mol Neurobiol. 1999 Feb;19(1):67-78. doi: 10.1023/a:1006964507916.
2
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease.
Lancet Neurol. 2013 Jan;12(1):84-91. doi: 10.1016/S1474-4422(12)70295-8.
3
Cell transplantation for Parkinson's disease: present status.
Cell Mol Neurobiol. 2004 Jun;24(3):301-16. doi: 10.1023/b:cemn.0000022764.94760.3f.
4
[Experimental clinical transplantation in patients with Parkinson disease. Experimental background and clinical picture].
Ugeskr Laeger. 1991 Dec 9;153(50):3554-8.
5
Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: basic and clinical studies.
Brain Res Bull. 1996;40(1):1-19. doi: 10.1016/0361-9230(96)00010-x.
6
Cells of the sympathoadrenal lineage: biological properties as donor tissue for cell-replacement therapies for Parkinson's disease.
Brain Res Brain Res Rev. 2005 Sep;49(2):343-54. doi: 10.1016/j.brainresrev.2005.01.004. Epub 2005 Mar 2.
7
Neuropathology of fetal nigra transplants for Parkinson's disease.
Prog Brain Res. 2000;127:333-44. doi: 10.1016/s0079-6123(00)27016-7.
8
Clinical observations after neural transplantation in Parkinson's disease.
Prog Brain Res. 2000;127:299-320. doi: 10.1016/s0079-6123(00)27014-3.
9
Transplants in Parkinson's disease.
Eur Neurol. 1991;31 Suppl 1:17-27. doi: 10.1159/000116717.
10
Cellular replacement therapy for Parkinson's disease--where we are today?
Neuroscientist. 2002 Oct;8(5):457-88. doi: 10.1177/107385802237703.
本文引用的文献
1
Improved cryopreservative medium suitable for the freeze-storage and transplantation of fetal neural tissues.
Restor Neurol Neurosci. 1993 Jan 1;6(1):73-81. doi: 10.3233/RNN-1993-6108.
2
The effect of a short-course treatment with FK506 on the survivability of rat-to-mouse cross-species neural graft.
Restor Neurol Neurosci. 1993 Jan 1;5(2):131-9. doi: 10.3233/RNN-1993-5203.
3
Chromaffin cell survival from both young and old donors is enhanced by co-grafts of polymer-encapsulated human NGF-secreting cells.
Neuroreport. 1996 Jul 29;7(11):1813-8. doi: 10.1097/00001756-199607290-00025.
4
Preliminary report of polymer-encapsulated dopamine-secreting cell grafting into the brain.
Cell Transplant. 1996 Sep-Oct;5(5 Suppl 1):S17-9. doi: 10.1016/0963-6897(96)00032-2.
5
Cografting with polymer-encapsulated human nerve growth factor-secreting cells and chromaffin cell survival and behavioral recovery in hemiparkinsonian rats.
J Neurosurg. 1996 Jun;84(6):1006-12. doi: 10.3171/jns.1996.84.6.1006.
6
Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: basic and clinical studies.
Brain Res Bull. 1996;40(1):1-19. doi: 10.1016/0361-9230(96)00010-x.
7
Neural transplantation and trophic factors in Parkinson's disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine-secreting cell grafting.
Exp Neurol. 1996 Feb;137(2):333-44. doi: 10.1006/exnr.1996.0034.
8
Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report.
J Neurosurg. 1996 Apr;84(4):685-9. doi: 10.3171/jns.1996.84.4.0685.
9
Histological analysis of microencapsulated dopamine-secreting cells in agarose/poly(styrene sulfonic acid) mixed gel xenotransplanted into the brain.
Exp Neurol. 1996 Mar;138(1):169-75. doi: 10.1006/exnr.1996.0055.
10
Xenogeneic dopaminergic grafts reverse behavioral deficits induced by 6-OHDA in rodents: effect of 15-deoxyspergualin treatment.
Neurosci Lett. 1993 Nov 26;163(1):81-4. doi: 10.1016/0304-3940(93)90234-c.
Zotero 插件